Table 5.
Risk relationship of scores with selected variables∗1.
| Score∗2 | Total | Age ≥ 52 yrs (n = 117) |
PR negative (n = 112) |
MRE11 positive cells > 50% (n = 113) |
BMI ≥ 24 (n = 176) |
HER2 negative (n = 164) |
|||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| N | N | % | N | % | N | % | N | % | N | % | |
| ≤5 | 161 | 51 | 31.68 | 47 | 29.19 | 61 | 37.89 | 96 | 59.63 | 103 | 63.98 |
| 6 | 43 | 27 | 62.79 | 27 | 62.79 | 20 | 46.51 | 32 | 74.42 | 27 | 62.79 |
| 7 | 24 | 18 | 75.00 | 16 | 66.67 | 13 | 54.17 | 24 | 100.00 | 14 | 58.33 |
| 8 | 17 | 13 | 76.47 | 13 | 76.47 | 12 | 70.59 | 15 | 88.24 | 13 | 76.47 |
| 9 | 8 | 7 | 87.50 | 8 | 100.00 | 6 | 75.00 | 8 | 100.00 | 6 | 75.00 |
| 10 | 1 | 1 | 100.00 | 1 | 100.00 | 1 | 100.00 | 1 | 100.00 | 1 | 100.00 |
PR: progesterone receptor; MRE11: meiotic recombination 11; BMI: body mass index; HER2: human epidermal growth factor receptor 2.
∗1Dataset was retrieved from our previous study (n = 254) [9].
∗2Cumulated score representing the number of risk properties of the selected clinicopathologic variables in the subjects. The selected clinicopathologic variables included tumor size, tumor stage, ER, HT, LN metastasis, age, PR, BMI, MRE11 positive cells, and HER2.